149 related articles for article (PubMed ID: 36322383)
1. Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
Futatsugi K; Cabral S; Kung DW; Huard K; Lee E; Boehm M; Bauman J; Clark RW; Coffey SB; Crowley C; Dechert-Schmitt AM; Dowling MS; Dullea R; Gosset JR; Kalgutkar AS; Kou K; Li Q; Lian Y; Loria PM; Londregan AT; Niosi M; Orozco C; Pettersen JC; Pfefferkorn JA; Polivkova J; Ross TT; Sharma R; Stock IA; Tesz G; Wisniewska H; Goodwin B; Price DA
J Med Chem; 2022 Nov; 65(22):15000-15013. PubMed ID: 36322383
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
Amin NB; Saxena AR; Somayaji V; Dullea R
Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
[TBL] [Abstract][Full Text] [Related]
3. Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat.
Sharma R; Dowling MS; Futatsugi K; Kalgutkar AS
Chem Res Toxicol; 2023 Jun; 36(6):934-946. PubMed ID: 37148271
[TBL] [Abstract][Full Text] [Related]
4. Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.
Sawant-Basak A; Bergman AJ; Mancuso J; Tripathy S; Gosset JR; Mendes da Costa L; Esler WP; Calle RA
Clin Transl Sci; 2024 Feb; 17(2):e13687. PubMed ID: 38362827
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
Amin NB; Darekar A; Anstee QM; Wong VW; Tacke F; Vourvahis M; Lee DS; Charlton M; Alkhouri N; Nakajima A; Yunis C
BMJ Open; 2022 Mar; 12(3):e056159. PubMed ID: 35354614
[TBL] [Abstract][Full Text] [Related]
6. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
Amin NB; Carvajal-Gonzalez S; Purkal J; Zhu T; Crowley C; Perez S; Chidsey K; Kim AM; Goodwin B
Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776293
[TBL] [Abstract][Full Text] [Related]
7. The Postnatal Resolution of Developmental Toxicity Induced by Pharmacological Diacylglycerol Acyltransferase 2 (DGAT2) Inhibition During Gestation in Rats.
Catlin NR; Bowman CJ; Campion SN; Lewis EM; Nowland WS; Stethem C; Cappon GD
Toxicol Sci; 2022 Sep; 189(2):225-236. PubMed ID: 35866640
[TBL] [Abstract][Full Text] [Related]
8. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
9. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis.
Yenilmez B; Wetoska N; Kelly M; Echeverria D; Min K; Lifshitz L; Alterman JF; Hassler MR; Hildebrand S; DiMarzio C; McHugh N; Vangjeli L; Sousa J; Pan M; Han X; Brehm MA; Khvorova A; Czech MP
Mol Ther; 2022 Mar; 30(3):1329-1342. PubMed ID: 34774753
[TBL] [Abstract][Full Text] [Related]
10. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
Calle RA; Amin NB; Carvajal-Gonzalez S; Ross TT; Bergman A; Aggarwal S; Crowley C; Rinaldi A; Mancuso J; Aggarwal N; Somayaji V; Inglot M; Tuthill TA; Kou K; Boucher M; Tesz G; Dullea R; Bence KK; Kim AM; Pfefferkorn JA; Esler WP
Nat Med; 2021 Oct; 27(10):1836-1848. PubMed ID: 34635855
[TBL] [Abstract][Full Text] [Related]
11. Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-Life.
Filipski KJ; Edmonds DJ; Garnsey MR; Smaltz DJ; Coffman K; Futatsugi K; Lee J; O'Neil SV; Wright A; Nason D; Gosset JR; Orozco CC; Blackler D; Fakhoury G; Gutierrez JA; Perez S; Ross T; Stock I; Tesz G; Dullea R
ACS Med Chem Lett; 2023 Oct; 14(10):1427-1433. PubMed ID: 37849537
[TBL] [Abstract][Full Text] [Related]
12. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
Ganji SH; Kashyap ML; Kamanna VS
Metabolism; 2015 Sep; 64(9):982-90. PubMed ID: 26024755
[TBL] [Abstract][Full Text] [Related]
13. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel class of diacylglycerol acyltransferase 2 inhibitors with a 1H-pyrrolo[2,3-b]pyridine core.
Kim MO; Lee S; Choi K; Lee S; Kim H; Kang H; Choi M; Kwon EB; Kang MJ; Kim S; Lee HJ; Lee HS; Kwak YS; Cho S
Biol Pharm Bull; 2014; 37(10):1655-60. PubMed ID: 25099343
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Badi RM; Mostafa DG; Khaleel EF; Satti HH
Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):545-555. PubMed ID: 30773673
[TBL] [Abstract][Full Text] [Related]
16. Targeting ACC for NASH resolution.
Zhang XJ; Cai J; Li H
Trends Mol Med; 2022 Jan; 28(1):5-7. PubMed ID: 34844875
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2).
Pabst B; Futatsugi K; Li Q; Ahn K
Biochemistry; 2018 Dec; 57(51):6997-7010. PubMed ID: 30422629
[TBL] [Abstract][Full Text] [Related]
18. Role of diacylglycerol O-acyltransferase (DGAT) isoforms in bovine hepatic fatty acid metabolism.
Yang W; Wang S; Loor JJ; Lopes MG; Zhao Y; Ma X; Li M; Zhang B; Xu C
J Dairy Sci; 2022 Apr; 105(4):3588-3600. PubMed ID: 35181144
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
20. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
